Clinical Trial Update: mFOLFIRI as the Second Line Chemotherapy for Advanced Esophageal Carcinoma After Failure of 1st Line Treatment of Paclitaxel/DDP : a Phase II Single Center Prospective Clinical Trial [Phase 2]

View source ↗

Summary

Phase II single-center prospective trial evaluating the modified FOLFIRI regimen as second-line chemotherapy for advanced esophageal cancer after failure of fir…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Esophageal Cancer

Drugs mentioned

• mFOLFIRI

Snippet

Sponsor: Peking University | Conditions: Advanced Esophageal Carcinoma | Phase 2 | Status: UNKNOWN